Phase I/II Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Next Previous
Trial Profile

Phase I/II Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Ipilimumab; Nivolumab
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 12 Mar 2018 According to a Bavarian Nordic media release, data will begin to emerge in 2018.
    • 16 Sep 2017 Planned number of patients changed from 65 to 29.
    • 16 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top